Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Monitoring coagulation factor replacement therapy of selected extended half-life coagulation factor replacements
Aiding in the diagnosis of hemophilia A using a 2-stage assay, especially when the 1-stage assay was normal
This assay is indicated in situations where there is a clinical suspicion of hemophilia A diagnosis, but the 1-stage Factor VIII assay is normal. However, recent guidelines also recommend this assay be performed in addition to the 1-stage assay in the initial workup of hemophilia A.
Testing for autoantibodies to FVIII in the presence of a low FVIII activity may be clinically indicated. For adding on FVIII inhibitor, contact Mayo Clinic Laboratories within 7 days to assess if adequate plasma sample is available.
Coagulation testing is highly complex, often requiring the performance of multiple assays and correlation with clinical information. For that reason, we recommend requesting a coagulation consultation.
See Hemophilia Testing Algorithm in Special Instructions.
Chromogenic